Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

r of this year.
  • Improved the balance sheet by retiring $17.0 million out of the total $22.0 million principle amount of outstanding convertible notes. These notes carried a coupon rate of 4.75% payable semi-annually and had a maturity date of July 15, 2009. Under the terms of the early retirement, Novavax paid 70% of the principal plus accrued and unpaid interest, or $12.1 million, in cash and issued 2,040,000 shares of its common stock for the remaining 30% of the principal, valued in the transaction as approximately $5.1 million. The remaining $5.0 million in outstanding convertible notes will be due on July 15, 2009 and can be paid up to 50% in stock at maturity at Novavax's option.
  • Increased liquidity by raising $11.0 million from sale of 12.5 million shares of common stock to a wholly owned subsidiary of Cadila Pharmaceuticals and raising approximately $7.5 million from the sale of approximately 3.1 million shares of common stock under the sales agreement with Wm Smith & Co.

  • "We are pleased with the significant clinical, corporate, and financial progress we have made in the past few months," said Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer. "We have made substantial progress in advancing our VLP based influenza vaccines over the past three years. The recent emergence of the novel influenza A (H1N1) virus highlights the potential value of our recombinant VLP technology as we can produce a genetically matched vaccine to the outbreak strain in about half the time of traditional vaccine technologies. We are in communication with governments and health authorities around the world and will help in any way possible. With the improvement in our financial position, we are in a much stronger position to continue development of our vaccine pipeline and pursue partnerships."

    The anticipated milestones for the remainder of 2009 include:

    <
    '/>"/>
    SOURCE Novavax, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
    2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
    3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
    4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
    5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
    6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
    7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
    8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
    9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
    10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
    11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/22/2015)... May 22, 2015 Charm Sciences, ... Department of Agriculture (USDA), Grain Inspection, Packers and ... contract to Charm Sciences to monitor aflatoxin in ... (water-based) and ROSA FAST Aflatoxin Quantitative Test (solvent-based). ... Test uses Water Extraction Technology to extract ...
    (Date:5/22/2015)... 22, 2015 Knowledgent , the ... that explores the potential of big data analytics in ... was developed to help life sciences and healthcare organizations ... to gain critical business insights. , The life sciences ... data driven by patient profiling, compliance and regulatory requirements, ...
    (Date:5/22/2015)... 22, 2015 Baylor Research Institute (BRI) ... Genomics Research Institute (TGen) in Phoenix, AZ ... accelerating early detection and treatments for patients with a broad ... will lead to new clinical trials and access to technology ... gap from bench to bedside across Baylor Scott ...
    (Date:5/21/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... proprietary technologies and products for advanced microarray diagnostics, today ... fiscal quarter ended March 31, 2015. ... with our existing customers and to develop new opportunities," ... SQI. "The delivery of a fully automated sqidlite™ system ...
    Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8
    ... TOWN, South Africa, Oct. 11, Iomai Corporation (Nasdaq: ... Glenn, M.D., presented an,overview of the clinical data for ... a vaccine could have on,global health at the Keystone ... Town, South Africa. Last month, Dr. Glenn presented ...
    ... quarter of 2007 increased 25 percent compared to the third quarter ... ... (NYSE: CRY ),a biomaterials, medical device and tissue processing company, ... 2007 were approximately $21.9 million compared to $20.0 million in the,third ...
    ... Genome Sciences (UK),Ltd "OGeS" announces today that it ... the appointment of Sir Walter Bodmer, currently,Head of ... of Molecular Medicine at the University of Oxford, ... changes which,lead to the development of colorectal cancer. ...
    Cached Biology Technology:Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference 2Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference 3Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 2CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 3CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 4CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million 5Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board 2Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board 3
    (Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
    (Date:5/21/2015)... 21, 2015 The Sync Project™ , ... for health, today announced a collaborative partnership with ... will center on collaboration on original research, joint course ... in the collaboration, The Sync Project and BerkleeICE are ... Medicine" in the 2015-2016 academic year.  ...
    (Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
    Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
    ... Tech in the United States have determined the structure ... xanthurenic acid (XA) in Anopheles gambiae, the malaria carrying ... reproduction of the malaria parasite (Plasmodium falciparum) in A. ... be an avenue for development of drugs and insecticides ...
    ... show that regular use of popular prescription pain relievers may ... percent and may offer similar benefit in the prevention of ... were released today at the annual meeting of the American ... believe this is the first study to show that selective ...
    ... Have you ever tried to do the limbo? For ants ... Zurich have discovered that ants are able to learn how ... they can successfully crawl under it without slowing down. Tobias ... Annual Meeting for the Society for Experimental Biology on Tuesday ...
    Cached Biology News:Oxidation defense in mosquitoes benefits malaria parasite 2COX-2 inhibitors significantly reduce risk of cancer 2
    ... GeneMaths XT is undoubtedly the most complete ... advanced concept of layers and subsets makes ... layers for different data outputs, for example ... etc., as well as different subsets of ...
    ...
    ...
    ... for Mac OS X provides the most ... protein sequence analysis and molecular biology data ... 1). With Vector NTI Suite you can ... publicize diverse types of molecular biology data ...
    Biology Products: